Posted by Michael Wonder on 24 Oct 2022
Novaliq announces FDA acceptance of the new drug application for CyclASol for the treatment of dry eye disease
25 October 2022 - PDUFA target action date is 8 June 2023.
Novaliq today announced that the U.S. FDA has accepted the new drug application for CyclASol (cyclosporin ophthalmic solution), a first of its kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease.
